Meeting
2022 ASCO Annual Meeting
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.
Authors
Sujana Movva
Memorial Sloan Kettering Cancer Center, New York, NY
Sujana Movva , Viswatej Avutu , Ping Chi , Mark Andrew Dickson , Mrinal M. Gounder , Ciara Marie Kelly , Mary Louise Keohan , Benjamin Alexander Nacev , Evan Rosenbaum , Katherine Anne Thornton , Seth M. Cohen , Martee Leigh Hensley , Jason A. Konner , Alison M. Schram , Li-Xuan Qin , Robert A Lefkowitz , Joseph Patrick Erinjeri , Sandra P. D'Angelo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04784247
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11588)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11588
Abstract #
TPS11588
Poster Bd #
489a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.
First Author: Sujana Movva
Poster
2019 ASCO Annual Meeting
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
First Author: Vicky Makker
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
First Author: Matthew H. Taylor
Poster
2020 ASCO Virtual Scientific Program
Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Lillian L. Siu